Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes of Medicare Fee-for-Service Beneficiaries Meeting the Eligibility Criteria for the DREAMM-7 and DREAMM-8 Clinical Trials

Simon McNamara, Natalie Boytsov, Peter Feng Wang, Maya Hanna, Anjali Franco, Benjamin Lewing, Barth Kelly, Joseph Tkacz

Blood (2023) 142 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2023-181668

Published: 2023

Journal Articles

Characterization of Dysregulated Transcription in TP53 -Mutated AML Subpopulations

Ghayas C. Issa, Vakul Mohanty, Edward Ayoub, Feng Wang, Jake Leighton, Xiaogang Wu, Aram Bidikian, Tallie Patsilevas, Zoe Alaniz, Jabra Zarka, Rashmi Kanagal-Shamanna, Andy Futreal, Naval Daver, Marina Konopleva, Nicholas Navin, Jianhua Zhang, Ken Chen, Michael Andreeff

Blood (2022) 140 (Supplement 1): 6323–6325.

https://doi.org/10.1182/blood-2022-168136

Published: 2022

Journal Articles

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Bo Dai, Feng Wang, Ying Wang, Jiayan Zhu, Yunxuan Li, Tingting Zhang, Luyao Zhao, Li-Ling Wang, Wenhui GAO, Junmin Li, Aibin Liang, Hong-hu Zhu, Ke Li, Jiong Hu

Blood (2022) 140 (Supplement 1): 5924–5925.

https://doi.org/10.1182/blood-2022-156735

Published: 2022

Journal Articles

Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53- mutated AML

Ghayas C. Issa, Aram Bidikian, Edward Ayoub, Feng Wang, Vakul Mohanty, Jake Leighton, Xiaogang Wu, Tallie Patsilevas, Zoe Alaniz, Jabra Zarka, Rashmi Kanagal-Shamanna, Naval Daver, Andy Futreal, Marina Konopleva, Nicholas Navin, Jianhua Zhang, Ken Chen, Michael Andreeff

Blood (2022) 140 (Supplement 1): 6267–6269.

https://doi.org/10.1182/blood-2022-165439

Published: 2022

Journal Articles

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Joshua Richter, Peter Feng Wang, Alexa Molinari, Boris Gorsh, Natalie Boytsov, Suzanne Landi, Sue Perera, Prani Paka, Teresa Palumbo, Mei Sheng Duh, Christopher Yee, Anamika Khanal, Sonia Gupta, Ajai Chari

Blood (2022) 140 (Supplement 1): 4338–4340.

https://doi.org/10.1182/blood-2022-164918

Published: 2022

Journal Articles

Efficacy and Safety of Third-Line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

Maya Hanna, Justyna Chorazy, Ike Iheanacho, Boris Gorsh, Peter Feng Wang, Prani Paka, Sue Perera

Blood (2022) 140 (Supplement 1): 12559–12560.

https://doi.org/10.1182/blood-2022-167521

Published: 2022

Journal Articles

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

Natalie Boytsov, Boris Gorsh, Seth Anderson, Peter Feng Wang, Sue Perera, Meg Franklin

Blood (2022) 140 (Supplement 1): 12554–12555.

https://doi.org/10.1182/blood-2022-167184

Published: 2022

Journal Articles

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL

Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Dong Liu, Lei Liu, Feiqiu Wen, Ji-shuai Zhang, Feng Wang, Ze-lin Liu, Yu J. Cao

Blood (2022) 140 (16): 1790–1802.

https://doi.org/10.1182/blood.2022016243

Published: 2022

Includes: Supplemental data

Journal Articles

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Blood (2022) 140 (16): 1753–1763.

https://doi.org/10.1182/blood.2021014956

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study

Feng Wang, Boris Gorsh, Maral DerSarkissian, Prani Paka, Rachel Bhak, Natalie Boytsov, Miriam L. Zichlin, Leah Sansbury, Christopher W. Yee, Shannon Ferrante, Anamika Khanal, Ahmed Noman, Mei Sheng Duh

Blood (2021) 138 (Supplement 1): 2705.

https://doi.org/10.1182/blood-2021-152301

Published: 2021

Journal Articles

A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma and Prior Exposure to Daratumumab, an Immunomodulatory Agent, and a Proteasome Inhibitor

Natalie Boytsov, Anissa Cyhaniuk, Gary Leung, Feng Wang, Cosmina Hogea, Matthew Lee Smith, Pallavi Mudumby

Blood (2021) 138 (Supplement 1): 4019.

https://doi.org/10.1182/blood-2021-152230

Published: 2021

Journal Articles

Real-World Assessment of Prior Treatment Patterns in Patients Receiving Belantamab Mafodotin Using a Longitudinal Pharmacy and Medical Open Source Claims Database

Natalie Boytsov, Karen Stockl, Chi-Chang Chen, Feng Wang, Xin Wang, Yao Cao, Allison Doherty, Prani Paka

Blood (2021) 138 (Supplement 1): 4973.

https://doi.org/10.1182/blood-2021-152242

Published: 2021

Journal Articles

A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma Following Sequential Treatment with Lenalidomide and a Proteasome Inhibitor

Natalie Boytsov, Anissa Cyhaniuk, Gary Leung, Feng Wang, Cosmina Hogea, Matthew Lee Smith, Pallavi Mudumby

Blood (2021) 138 (Supplement 1): 4963.

https://doi.org/10.1182/blood-2021-152731

Published: 2021

Journal Articles

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Koichi Takahashi, Anna Jonasova, Selina M. Luger, Aref Al-Kali, David Valcarcel, Erica D. Warlick, Maria Diez-Campelo, Michael K Keng, Feng Wang, Ken Furudate, Patrick S. Zbyszewski, Matthew Parris, Steven M. Fruchtman, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2021-152048

Published: 2021

Journal Articles

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Curtis Lachowiez, Courtney D. DiNardo, Kiyomi Morita, Ken Furudate, Feng Wang, Tomoyuki Tanaka, Sa A Wang, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Joseph D. Khoury, Keyur Patel, L. Jeffrey Medeiros, Marina Konopleva, Farhad Ravandi, Koichi Takahashi, Sanam Loghavi

Blood (2021) 138 (Supplement 1): 607.

https://doi.org/10.1182/blood-2021-148971

Published: 2021

Journal Articles

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood (2021) 138 (18): 1733–1739.

https://doi.org/10.1182/blood.2020010483

Published: 2021

Includes: Supplemental data

Journal Articles

Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis

Jia-feng Wang, Yun-peng Wang, Jian Xie, Zhen-zhen Zhao, Sahil Gupta, Yu Guo, Song-hui Jia, Jean Parodo, John C. Marshall, Xiao-ming Deng

Blood (2021) 138 (9): 806–810.

https://doi.org/10.1182/blood.2020009417

Published: 2021

Includes: Supplemental data

Journal Articles

Real-World Incidence and Clinical and Economic Burden of Managing Ocular Events in Patients with Active Multiple Myeloma

Feng Wang, PhD MPH, BS in MDcine, Shannon Ferrante, PhD, Eric M Maiese, PhD, Jenny Willson, PhD, Chi-Chang Chen, PhD, Sasikiran Nunna, PhD, Kainan Sun, PhD, David M Kleinman, MD, Leah Sansbury, PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139265

Published: 2020

Journal Articles

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Yuya Sasaki, MDPhD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P Andrew Futreal, PhD, Feng Wang, PhD, Ken Furudate, DDM, PhD, Rebecca Garris, MSc, Koichi Takahashi, MD PhD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136676

Published: 2020

Journal Articles

Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms

Hussein A Abbas, MDPhD, Feng Wang, PhD, Yue Wei, PhD, Hui Yang, MD PhD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Faezeh Darbaniyan, PhD, Jianhua Zhang, PhD, Andy Futreal, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140142

Published: 2020

NARROW

Real-World Outcomes of Medicare Fee-for-Service Beneficiaries Meeting the Eligibility Criteria for the DREAMM-7 and DREAMM-8 Clinical Trials

Characterization of Dysregulated Transcription in TP53 -Mutated AML Subpopulations

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53- mutated AML

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Efficacy and Safety of Third-Line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study

A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma and Prior Exposure to Daratumumab, an Immunomodulatory Agent, and a Proteasome Inhibitor

Real-World Assessment of Prior Treatment Patterns in Patients Receiving Belantamab Mafodotin Using a Longitudinal Pharmacy and Medical Open Source Claims Database

A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma Following Sequential Treatment with Lenalidomide and a Proteasome Inhibitor

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis

Real-World Incidence and Clinical and Economic Burden of Managing Ocular Events in Patients with Active Multiple Myeloma

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only